Foghorn Therapeutics (FHTX)

• Market cap: $211M
• 1 day: 9.51%
• 5 days: 16.56%
• 1 month: -17.39%
• 3 months: -11.83%
• 6 months: -50.90%
• Year to date: -17.21%
• 1 year: -34.26%
• 5 years: -79.03%
• 10 years: -79.03%
• Sector: Healthcare
• Industry: Biotechnology

About: Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Employees: 112

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

167% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 12

100% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 8

9% more funds holding

Funds holding: 79 [Q3] → 86 (+7) [Q4]

0.11% more ownership

Funds ownership: 72.29% [Q3] → 72.39% (+0.11%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

49% less capital invested

Capital invested by funds: $372M [Q3] → $190M (-$182M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 163% upside
• Avg. target: $11.50 203% upside
• High target: $13 242% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 27% 1-year accuracy 95 / 352 met price target	242% upside $13	Buy Reiterated	7 Mar 2025
B. Riley Securities Kalpit Patel 9% 1-year accuracy 1 / 11 met price target	163% upside $10	Buy Initiated	30 Jan 2025